Redcare Pharmacy Faces Strategic Overhaul Amid Intensifying Competition

Redcare Pharmacy announces major board and CFO changes for 2026 to counter new rivals like dm and Rossmann, as its stock hits a 52-week low.

Redcare Pharmacy is navigating a critical strategic juncture. The online pharmacy is undertaking a sweeping leadership transformation, even as major drugstore chains aggressively expand their digital operations, directly threatening its core business. An upcoming shareholder meeting in April 2026 is poised to formalize this reset, occurring at a moment when investor confidence has been significantly eroded.

Leadership Shake-Up Aims to Steer New Course

The company’s strategic response centers on a comprehensive personnel overhaul set for approval at the Annual General Meeting on April 15, 2026. The proposed changes involve the departure of three long-standing supervisory board members and the election of new candidates:
* Anja Hendel (Supervisory Board Candidate)
* Max Müller (Supervisory Board Candidate)
* Peter Schmid von Linstow (Supervisory Board Candidate)
* Hendrik Krampe (CFO Candidate)

Considerable expectations are placed on the designated finance chief, Hendrik Krampe. The company anticipates his two decades of experience at Amazon and eBay will bring fresh strategic direction and drive more efficient scaling of its digital marketplace.

The newly configured leadership team will face its first major financial test shortly after the transition. Redcare Pharmacy is scheduled to release its first-quarter results on May 6, 2026, providing an early indicator of whether the management changes can swiftly impact profitability.

Market Pressure and Defensive Strengths

Intensifying competitive pressure is a primary factor behind the strategic shift. The recent market entry of dm with its 'dm-med' platform in December 2025, coupled with Rossmann's announcement of similar plans for this year, has spooked investors. Their primary concern is the potential erosion of Redcare's lucrative over-the-counter (OTC) medication business. This competitive anxiety is reflected starkly in the company's share price performance. As of Friday, the stock hit a new 52-week low of €33.54, highlighting a dramatic loss of approximately 50% in value since the start of the year alone. Interestingly, recent Hazeltree data from March suggests some short sellers have begun covering their positions at these depressed levels.

Despite the headwinds in the OTC segment, Redcare maintains a crucial defensive moat in the regulated prescription (Rx) medicine market. Rossmann has confirmed its planned online pharmacy will not offer prescription medications, preserving a significant barrier to entry for competitors in this space. Bolstered by its CardLink license, valid until January 2027, and the integration of the GesundheitsID, the company projects Rx-related revenues exceeding €670 million for 2026.

While Redcare's total revenue saw robust growth last year, reaching €2.9 billion, its profitability targets for the current period remain modest. Management is guiding for an adjusted EBITDA margin of at least 2.5%, a goal the new team must now pursue within an increasingly challenging competitive landscape.